Hims & Hers Health, Inc. Class A Common Stock (HIMS)

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Patients will be able to access Novo Nordisk’s direct-to-patient online pharmacy, NovoCare, through the telehealth providers.

The companies will collaborate to improve access to weight-loss drugs in the U.S.

Since April 2020, the S&P 500 has delivered a total return of 92.9%. But one standout stock has nearly doubled the market - over the past five years, Hims & Hers Health has surged 172% to $26.89 per share. Its momentum hasn’t stopped as it’s also gained 25.8% in the last six months thanks to its solid quarterly results, beating the S&P by 32.6%.

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season.

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that trade tariffs could add upward pressure to inflation in the short term and complicate the Fed's efforts to stabilize the economy. He warned that such trade measures are "likely to move us further away from our goals," referring to the Fed's dual mandate of price stability and maximum employment. 

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

Based on technical and fundamental analysis of NYSE:HIMS we find: HIMS & HERS HEALTH INC (NYSE:HIMS) qualifies as a high growth stock and is consolidating.

A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most countries, sparking renewed optimism amid ongoing trade talks. The major stock indices rose as investors, growing impatient of seemingly irrational tariff actions, welcomed the pause as a sign of a more measured path forward. 

It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it.

U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07.

According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its platform, marking a significant expansion beyond its previous focus on lower-cost alternatives to Novo Nordisk's Wegovy. This move positioned the company to tap into the growing demand for weight loss solutions and attract a broader customer base. The company added, "As we look ahead, we plan to continue to expand our weight loss offering to deliver an even more holistic, personalized experience."

Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.

The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform.